At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 256 enrolled
Drug / intervention
Delafloxacin +2 moredrug
Likely dose
Delafloxacin 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid
In Brief
A Phase 2 clinical trial evaluating Delafloxacin, Linezolid, and 1 other intervention for Skin and Subcutaneous Tissue Bacterial Infections. Completed, enrolled 256 participants across 31 sites.
Detailed Summary
The purpose of this study is to compare clinical response to the measurement techniques of several objective measures of clinical efficacy for use in future ABSSSI (Acute Bacterial Skin and Skin Structure Infection) clinical trials
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedJan 2011
Primary CompletionNov 2011
TodayJul 2026
First PostedJan 26, 2011
Enrollment StartJan 1, 2011
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 15.4 years ago
Interventions
Delafloxacindrug
300mg IV every 12 hours for 5-14 days
Linezoliddrug
600mg IV every 12 hours for 5-14 days
Vancomycindrug
15mg/kg, up to 1250 mg, IV every 12 hours for 5-14 days